Report cover image

Global Hereditary Angioedema Therapeutics Market Size study, by Treatment Type (C-1 Esterase Inhibitor, Kallikrein Inhibitor), Route of Administration (Oral, Parenteral), Age Group (Pediatric, Adult), Distribution Channel (Hospital Pharmacies, Online Phar

Publisher Bizwit Research & Consulting
Published May 25, 2025
Length 285 Pages
SKU # BIZW20048153

Description

Global Hereditary Angioedema (HAE) Therapeutics Market is valued approximately at USD 4.1 billion in 2023 and is anticipated to grow with a vigorous CAGR of more than 9.20% over the forecast period 2024–2032. Hereditary angioedema, a rare but potentially life-threatening genetic disorder, manifests through sudden episodes of severe swelling in various parts of the body. As awareness increases and genetic screening becomes more prevalent, the demand for highly targeted therapies continues to rise. This has placed HAE at the forefront of innovation in the rare disease treatment landscape. Fueled by technological advancements and research collaborations, pharmaceutical companies are launching next-generation inhibitors that are transforming acute and prophylactic treatment paradigms.

The market's acceleration is driven by the evolution of treatment from conventional corticosteroids and antifibrinolytics to more refined and safer options such as C1-esterase inhibitors and kallikrein inhibitors. These agents offer improved efficacy with fewer side effects and longer half-lives, which drastically enhances patient quality of life and adherence. Furthermore, the introduction of oral medications as a replacement for intravenous or subcutaneous routes has widened access and reduced treatment burdens. This therapeutic shift reflects a broader industry trend toward personalization and convenience in chronic disease management, which resonates deeply with HAE patients managing lifelong conditions.

Parallel to therapeutic innovations, regulatory bodies have facilitated accelerated approvals of breakthrough drugs, catalyzing faster market penetration. Companies are strategically diversifying their product pipelines with both acute and prophylactic indications to cover a broader patient base. In addition, pricing strategies, patient assistance programs, and collaborations with rare disease advocacy groups are being actively leveraged to enhance market adoption. With a growing pediatric patient pool and increasing awareness among clinicians, there’s a measurable uptick in early diagnosis rates, further bolstering the demand for long-term, well-tolerated therapies.

Regionally, North America dominates the HAE therapeutics market owing to early product availability, favorable reimbursement systems, and robust patient registries. The United States, in particular, demonstrates strong market penetration with widespread clinical trial activity and an established network of rare disease specialists. Europe follows closely behind, propelled by collaborative research frameworks and government support for orphan drug development. Meanwhile, Asia Pacific is expected to experience the highest growth rate, fueled by expanding healthcare infrastructure, rising rare disease literacy, and the ongoing rollout of genomic medicine in nations like Japan, South Korea, and India.

Major market player included in this report are:
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Pharming Group N.V.
• BioCryst Pharmaceuticals, Inc.
• Ionis Pharmaceuticals, Inc.
• KalVista Pharmaceuticals, Inc.
• Attune Pharmaceuticals, Inc.
• Intellia Therapeutics, Inc.
• Adverum Biotechnologies, Inc.
• Arrowhead Pharmaceuticals, Inc.
• HAE Therapeutics
• Amgen Inc.
• AstraZeneca
• Regeneron Pharmaceuticals, Inc.
• F. Hoffmann-La Roche Ltd.

The detailed segments and sub-segment of the market are explained below:

By Treatment Type
• C-1 Esterase Inhibitor
• Kallikrein Inhibitor

By Route of Administration
• Oral
• Parenteral

By Age Group
• Pediatric
• Adult

By Distribution Channel
• Hospital Pharmacies
• Online Pharmacies

By Region:

North America
• U.S.
• Canada

Europe
• UK
• Germany
• France
• Spain
• Italy
• Rest of Europe

Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Rest of Asia Pacific

Latin America
• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa
• Saudi Arabia
• South Africa
• Rest of Middle East & Africa

Years considered for the study are as follows:
• Historical year – 2022
• Base year – 2023
• Forecast period – 2024 to 2032

Key Takeaways:
• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.

Table of Contents

285 Pages
Chapter 1. Global Hereditary Angioedema (HAE) Therapeutics Market Executive Summary
1.1. Global HAE Therapeutics Market Size & Forecast (2022 – 2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Treatment Type
1.3.2. By Route of Administration
1.3.3. By Age Group
1.3.4. By Distribution Channel
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global HAE Therapeutics Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability (Payer & Patient Perspectives)
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks & Orphan Designations
2.3.4.2. Technological Advancements in Genetic Screening
2.3.4.3. Patient Awareness & Advocacy
2.3.4.4. Healthcare Infrastructure
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global HAE Therapeutics Market Dynamics
3.1. Market Drivers
3.1.1. Increased Awareness and Early Diagnosis of HAE
3.1.2. Advances in Targeted C1-Esterase and Kallikrein Inhibitors
3.1.3. Shift to Oral Therapies Reducing Treatment Burden
3.2. Market Challenges
3.2.1. High Treatment Costs and Reimbursement Constraints
3.2.2. Limited Access and Infrastructure in Emerging Markets
3.3. Market Opportunities
3.3.1. Rapid Growth in Asia-Pacific Rare Disease Markets
3.3.2. Development of Next-Generation Long-Acting Molecules
3.3.3. Expansion of Pediatric Indications and Prophylactic Use
Chapter 4. Global HAE Therapeutics Market Industry Analysis
4.1. Porter’s Five Forces Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.1.6. Futuristic Approach to Porter’s Five Forces
4.1.7. Impact Analysis
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economic
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Top Investment Opportunities
4.4. Top Winning Strategies
4.5. Disruptive Trends
4.6. Industry Expert Perspectives
4.7. Analyst Recommendation & Conclusion
Chapter 5. Global HAE Therapeutics Market Size & Forecasts by Treatment Type 2022 – 2032
5.1. Segment Dashboard
5.2. Global HAE Market: Treatment-Type Revenue Trend Analysis, 2022 & 2032 (USD Billion)
5.2.1. C1-Esterase Inhibitor
5.2.2. Kallikrein Inhibitor
Chapter 6. Global HAE Therapeutics Market Size & Forecasts by Route of Administration 2022 – 2032
6.1. Segment Dashboard
6.2. Global HAE Market: Route-of-Administration Revenue Trend Analysis, 2022 & 2032 (USD Billion)
6.2.1. Oral
6.2.2. Parenteral
Chapter 7. Global HAE Therapeutics Market Size & Forecasts by Age Group 2022 – 2032
7.1. Segment Dashboard
7.2. Global HAE Market: Age-Group Revenue Trend Analysis, 2022 & 2032 (USD Billion)
7.2.1. Pediatric
7.2.2. Adult
Chapter 8. Global HAE Therapeutics Market Size & Forecasts by Distribution Channel 2022 – 2032
8.1. Segment Dashboard
8.2. Global HAE Market: Distribution-Channel Revenue Trend Analysis, 2022 & 2032 (USD Billion)
8.2.1. Hospital Pharmacies
8.2.2. Online Pharmacies
Chapter 9. Global HAE Therapeutics Market Size & Forecasts by Region 2022 – 2032
9.1. North America
9.1.1. U.S.
9.1.1.1. Treatment-Type breakdown size & forecasts, 2022 – 2032
9.1.1.2. Route-of-Administration breakdown size & forecasts, 2022 – 2032
9.1.2. Canada
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. CSL Behring
10.1.2. Takeda Pharmaceutical Company Limited
10.1.3. Pharming Group N.V.
10.2. Top Market Strategies
10.3. Company Profiles
10.3.1. CSL Behring
10.3.1.1. Key Information
10.3.1.2. Overview
10.3.1.3. Financial (Subject to Data Availability)
10.3.1.4. Product Summary
10.3.1.5. Market Strategies
10.3.2. Takeda Pharmaceutical Company Limited
10.3.3. Pharming Group N.V.
10.3.4. BioCryst Pharmaceuticals, Inc.
10.3.5. Ionis Pharmaceuticals, Inc.
10.3.6. KalVista Pharmaceuticals, Inc.
10.3.7. Attune Pharmaceuticals, Inc.
10.3.8. Intellia Therapeutics, Inc.
10.3.9. Adverum Biotechnologies, Inc.
10.3.10. Arrowhead Pharmaceuticals, Inc.
10.3.11. HAE Therapeutics
10.3.12. Amgen Inc.
10.3.13. AstraZeneca
10.3.14. Regeneron Pharmaceuticals, Inc.
10.3.15. F. Hoffmann-La Roche Ltd.
Chapter 11. Research Process
11.1. Research Process
11.1.1. Data Mining
11.1.2. Analysis
11.1.3. Market Estimation
11.1.4. Validation
11.1.5. Publishing
11.2. Research Attributes
List of Tables
TABLE 1. Global HAE Therapeutics Market, report scope
TABLE 2. Global HAE Market estimates & forecasts by Region 2022 – 2032 (USD Billion)
TABLE 3. Global HAE Market estimates & forecasts by Treatment Type 2022 – 2032 (USD Billion)
TABLE 4. Global HAE Market estimates & forecasts by Route of Administration 2022 – 2032 (USD Billion)
TABLE 5. Global HAE Market estimates & forecasts by Age Group 2022 – 2032 (USD Billion)
TABLE 6. Global HAE Market estimates & forecasts by Distribution Channel 2022 – 2032 (USD Billion)
TABLE 7. Global HAE Market by segment, estimates & forecasts, 2022 – 2032 (USD Billion)
TABLE 8. Global HAE Market by region, estimates & forecasts, 2022 – 2032 (USD Billion)
TABLE 9. U.S. HAE Market estimates & forecasts, 2022 – 2032 (USD Billion)
TABLE 10. U.S. HAE Market estimates & forecasts by segment, 2022 – 2032 (USD Billion)
TABLE 11. Canada HAE Market estimates & forecasts, 2022 – 2032 (USD Billion)
TABLE 12. Canada HAE Market estimates & forecasts by segment, 2022 – 2032 (USD Billion)
…
TABLE 20. Canada HAE Market estimates & forecasts by segment, 2022 – 2032 (USD Billion)
(Full list exceeds 100 tables; updated in final deliverable)
List of Figures
FIGURE 1. Global HAE Market, research methodology
FIGURE 2. Global HAE Market, market estimation techniques
FIGURE 3. Global HAE Market size estimates & forecast methods
FIGURE 4. Global HAE Market, key trends 2023
FIGURE 5. Global HAE Market, growth prospects 2022 – 2032
FIGURE 6. Global HAE Market, Porter’s Five Forces model
FIGURE 7. Global HAE Market, PESTEL analysis
FIGURE 8. Global HAE Market, value chain analysis
FIGURE 9. Global HAE Market by segment, 2022 & 2032 (USD Billion)
FIGURE 10. Global HAE Market by segment, 2022 & 2032 (USD Billion)
...
FIGURE 20. Global HAE Market, company market share analysis (2023)
(Full list exceeds 50 figures; updated in final deliverable)

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us